Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $69.69, for a total transaction of $1,393,800.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,506,588.20. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Helen Torley also recently made the following trade(s):

• On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $70.21, for a total value of $702,100.00.
• On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00.
• On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00.

Halozyme Therapeutics Trading Up 0.9%

NASDAQ:HALO opened at $70.02 on Thursday. The stock has a fifty day simple moving average of $72.71 and a 200 day simple moving average of $70.76. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The firm has a market capitalization of $8.26 billion, a price-to-earnings ratio of 28.12, a price-to-earnings-growth ratio of 0.28 and a beta of 0.98. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The company’s quarterly revenue was up 51.6% on a year-over-year basis. During the same period last year, the business earned $1.26 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on HALO shares. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Benchmark increased their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Finally, Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Hold” and an average price target of $78.56.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of large investors have recently modified their holdings of the company. MidFirst Bank bought a new position in Halozyme Therapeutics during the 4th quarter valued at approximately $210,000. Pacer Advisors Inc. increased its position in Halozyme Therapeutics by 95.7% during the fourth quarter. Pacer Advisors Inc. now owns 937,293 shares of the biopharmaceutical company’s stock valued at $63,080,000 after acquiring an additional 458,419 shares during the last quarter. Corient Private Wealth LLC lifted its stake in shares of Halozyme Therapeutics by 1,552.5% in the 4th quarter. Corient Private Wealth LLC now owns 196,329 shares of the biopharmaceutical company’s stock worth $13,213,000 after purchasing an additional 184,448 shares during the period. Caitlin John LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth $465,000. Finally, First Citizens Bank & Trust Co. raised its stake in shares of Halozyme Therapeutics by 2.8% in the fourth quarter. First Citizens Bank & Trust Co. now owns 8,913 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 242 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.